An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Prescription use of two popular weight-loss drugs — semaglutide (brand names like Ozempic and Wegovy) and tirzepatide (brand name Zepbound or Mounjaro depending on indication) — is growing and expected to keep rising through 2025. Reports are noting a clear upward trend in doctors writing these medicines as more people seek them for obesity and related health problems. The story is mostly about how many more prescriptions are being written, not about a new scientific discovery. Semaglutide and tirzepatide are man-made versions of naturally occurring signals in the body that help control appetite and blood sugar. Semaglutide acts like a gut hormone that tells your brain “you’re full” and slows stomach emptying. Tirzepatide combines effects of two such hormones, so it can both reduce appetite and improve how the body handles glucose. Both are injected and were developed from research into hormones that regulate eating and metabolism. The news being reported is about prescription trends and demand — more people are getting these drugs. The source is tracking growth in prescriptions up to 2025. This isn’t a clinical trial or a new study showing better outcomes; it’s a report on usage and market dynamics. It doesn’t tell us that the drugs suddenly work differently or have new approvals. It likely reflects a mix of wider awareness, more doctors willing to prescribe them, and ongoing approvals for weight-loss use in broader groups of patients. Why this matters: these drugs are among the most effective medical options we have right now for losing significant weight and improving conditions like type 2 diabetes. If prescriptions keep rising, more patients could see health benefits, and the drugs will play a bigger role in how obesity is treated. It also affects access: greater demand can lead to supply issues, changes in insurance coverage, and more attention from regulators and clinicians about who should get them and how they’re used long term. There are important caveats. These medicines can have side effects such as nausea, diarrhea, or more serious issues in some people. They require medical supervision and aren’t suitable for everyone (for example, people with certain medical histories). Rising prescription numbers don’t answer questions about long-term safety, how long someone should stay on the drug, or whether weight returns after stopping. Also, coverage by insurers varies, and higher demand may make it harder for people who truly need them to get access. Bottom line: prescriptions for semaglutide and tirzepatide are rising and likely to keep rising through 2025, which could expand access and impact obesity care — but growth in prescriptions is different from new proof about how well the drugs work or how safe they are over decades.
Source: Olhar Digital